TVTX – travere therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at Wall St
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]
Form 4 Travere Therapeutics, For: Dec 01 Filed by: Cline Christopher R.
Form 144 Travere Therapeutics, Filed by: Cline Christopher R.
Form SCHEDULE 13G/A Travere Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Form SCHEDULE 13G/A Travere Therapeutics, Filed by: JANUS HENDERSON GROUP PLC
Form 4 Travere Therapeutics, For: Nov 04 Filed by: Calvin Sandra
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.